Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Opko Health is a diagnostics & research business based in the US. Opko Health shares (OPK) are listed on the NASDAQ and all prices are listed in US Dollars. Opko Health employs 5,767 staff and has a trailing 12-month revenue of around $1.2 billion.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $1.26 |
|---|---|
| 52-week range | $1.03 - $3.78 |
| 50-day moving average | $1.38 |
| 200-day moving average | $2.19 |
| Wall St. target price | $4.95 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.18 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.26 from 2023-01-26
| 1 week (2023-01-20) | -15.44% |
|---|---|
| 1 month (2022-12-27) | 17.76% |
| 3 months (2022-10-27) | -30.00% |
| 6 months (2022-07-27) | -48.99% |
| 1 year (2022-01-27) | -56.10% |
|---|---|
| 2 years (2021-01-27) | -77.34% |
| 3 years (2020-01-27) | 1.57 |
| 5 years (2018-01-26) | 4.88 |
| Revenue TTM | $1.2 billion |
|---|---|
| Gross profit TTM | $504.7 million |
| Return on assets TTM | -6.59% |
| Return on equity TTM | -18.67% |
| Profit margin | -25.98% |
| Book value | $2.11 |
| Market capitalisation | $1 billion |
TTM: trailing 12 months
We're not expecting Opko Health to pay a dividend over the next 12 months.
Over the last 12 months, Opko Health's shares have ranged in value from as little as $1.03 up to $3.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Opko Health's is 1.6979. This would suggest that Opko Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
OPKO Health, Inc. , a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
